 4D pharma PLC AIM:DDD, NASDAQ:LBPS jumped 27 in London trading after the company hit its primary efficacy target in a phase III trail of one of its lead assets in kidney cancer. Chief Executive Officer Duncan Peyton described the progress as potentially really meaningful for patients and their families, in a conference call on Wednesday. 